Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Destinasi Tirta Nusantara Tbk (PDES) vs Tempo Scan Pacific Tbk. (TSPC) Price & Performance

Destinasi Tirta Nusantara TbkTrade
Tempo Scan Pacific Tbk.Trade

Price performance (Past 24H)

Key statistics

Destinasi Tirta Nusantara Tbk vs Tempo Scan Pacific Tbk. — how do they compare? Destinasi Tirta Nusantara Tbk trades at Rp394 (market cap 283.14B, 308K 24h volume), while Tempo Scan Pacific Tbk. trades at Rp2,780 (market cap 12.58T, 235.2K 24h volume). The key difference: Tempo Scan Pacific Tbk. is far larger — about 44.4× Destinasi Tirta Nusantara Tbk's market cap, and Destinasi Tirta Nusantara Tbk is more actively traded (308K versus 235.2K). Which is the better fit depends on your goals.

PDESTSPC
Market Cap
283.14B12.58T
Volume
308K235.2K
Lot
3.08K2.35K
Turnover
119.93M649.94M
Average Price
389.392,763.37
Value
119.93M649.94M
Indicative Equilibrium Price
3942,780
Indicative Equilibrium Volume
659

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

PDES
View details
TSPC
View details

About Destinasi Tirta Nusantara Tbk

PT Destinasi Tirta Nusantara Tbk (the company) was established on 30 Oct 1999 based on Notaries Deed No. 36 and the deed of establishment was approved by the the Ministry of Justice dated Feb 23, 2000. The Company’s articles of association has been amended several times, most recently by notarial deed No. 187 and No.136 of Wijanto Suwongso, S.H., dated Jun 28, 2007 and 24 Oct 07, concerning among others, increase authorized, Paid up Capital, par value and public offering.

Read more on PDES

About Tempo Scan Pacific Tbk.

PT. Tempo Scan Pacific Tbk (the Company) was established in the Republic of Indonesia dated 20 May 1970, under its original name PT Scanchemie within the framework of the Domestic Capital Investment Law No. 6 year 1968, as amended by Law No. 12 year 1970, based on Notarial Deed No. 37 of Ridwan Suselo, S.H. The company is famous for such pharmaceutical products as Bodrex, Hemaviton and Neo-Rheumacyl.

Read more on TSPC